Aya A.G.,University of Nimes |
Ducloy-Bouthors A.-S.,Lille University Hospital Center |
Rugeri L.,Unite dHemostase Clinique |
Gris J.-C.,University of Nimes
Journal de Gynecologie Obstetrique et Biologie de la Reproduction | Year: 2014
Introduction. -Risk factors of maternal morbidity and mortality during postpartum hemorrhage(PPH) include non-optimal anesthetic management. As the anesthetic management of the initialphase is addressed elsewhere, the current chapter is dedicated to the management of severePPH.Methods -A literature search was performed using PubMed and Medline databases, and theCochrane Library, for articles published from 2003 up to and including 2013. Several keywordsrelated to anesthetic and critical care practice, and obstetrical management were used, invarious combinations. Guidelines from several societies and organisations were also read.Results -When PPH worsens, one should ask for additional team personnel (professionalconsensus). Patients should be monitored for heart rate, blood pressure, skin and mucosal pallor,bleeding at skin puncture sites, diuresis and the volume of genital bleeding (grade B). Becauseof the possible rapid worsening of coagulapathy, patients should undergo regular evaluation ofcoagulation status (professional consensus). Prevention and management of hypothermia shouldbe considered (professional consensus), by warming intravenous fluids and blood products, andby active body warming (grade C). Antibiotics should be given, if not already administered atthe initial phase (professional consensus). Vascular fluids must be given (grade B), the choicebeing left at the physician discretion. Blood products transfusion should be decided based onthe clinical severity of PPH (professional consensus). Priority is given to red blood cells (RBC)transfusion, with the aim to maintain Hb concentration > 8 g/dL. The first round of productscould include 3 units of RBC (professional consensus), and the following round 3 units of RBC,and 3 units of fresh frozen plasma (FFP). The FFP:RBC ratio should be kept between 1:2 and1:1 (professional consensus). Depending on the etiology of PPH, the early administration ofFFP is left at the discretion of the physician (professional consensus). Platelet count should bemaintained at > 50 G/L (professional consensus). During massive PPH, fibrinogen concentrationshould be maintained at > 2 g/L (professional consensus). Fibrinogen can be given without priorfibrinogen measurement in case of massive bleeding (professional consensus). General anesthe-sia should be considered in case of hemodynamic instability, even when an epidural catheter isin place (professional consensus).Conclusion-The anesthetic management aims to restore and maintain optimal respiratorystate and circulation, to treat coagulation disorders, and to allow invasive obstetrical andradiologic procedures. Clinical and instrumental monitoring are needed to evaluate the severityof PPH, to guide the choice of therapeutic options, and to assess treatments efficacy. © 2014 Published by Elsevier Masson SAS.
Ninivaggi M.,Synapse BV |
Apitz-Castro R.,Synapse BV |
Dargaud Y.,Unite dHemostase Clinique |
De Laat B.,Synapse BV |
And 2 more authors.
Clinical Chemistry | Year: 2012
BACKGROUND: The calibrated automated thrombogram (CAT) assay in plasma is a versatile tool to investigate patients with hypo- or hypercoagulable phenotypes. The objective was to make this method applicable for whole blood measurements. METHODS: Thin-layer technology and the use of a rhodamine 110-based thrombin substrate appear to be essential for a reliable thrombin generation (TG) assay in whole blood. Using this knowledge we developed a whole blood CAT-based assay. RESULTS: We demonstrated that the whole blood CAT-based assay is a sensitive and rapid screening test to assess function of the hemostatic system under more nearly physiological conditions than the TG assay in plasma. Under conditions of low tissue factor concentration (0.5 pmol/L) and 50% diluted blood, the intraassay CV of the thrombogram parameters, endogenous thrombin potential and thrombin peak height, were 6.7% and 6.5%, respectively. The respective interassay CVs were 12% and 11%. The mean interindividual variation (SD) of 40 healthy volunteers was 633 (146) nmol · min/L for the endogenous thrombin potential and 128 (23) nmol/L for the thrombin peak. Surprisingly, erythrocytes contributed more than platelets to the procoagulant blood cell membranes necessary for optimal TG. Statistically significant (P <0.001) and potentially clinically significant correlations were observed between circulating factor-VIII concentrations in blood of hemophilia A patients and endogenous thrombin potential (r = 0.62) and thrombin peak height (r = 0.58). CONCLUSIONS: We have developed a reliable method to measure TG in whole blood. The assay can be performed with a drop of blood and may provide a useful measurement of TG under more physiological conditions than plasma. © 2012 American Association for Clinical Chemistry.
Sorensen B.,Haemostasis Research Unit |
Dargaud Y.,Unite dHemostase Clinique |
Kenet G.,National Hemophilia Center |
Lusher J.,Childrens Hospital of Michigan |
And 3 more authors.
Haemophilia | Year: 2012
On-demand therapy with recombinant activated factor VII (rFVIIa) can provide effective haemostasis for spontaneous bleeds in haemophilia patients with inhibitors. However, treatment approaches vary amongst physicians, positively or negatively affecting outcomes. A panel of physicians proposed recommendations for securing and maintaining predictable efficacy with rFVIIa, comparing these with 'real-life' patient management, using a questionnaire circulated to other expert physicians from haemophilia care centres in Europe and the United States. For rFVIIa treatment of spontaneous bleeds in inhibitor patients, early intervention with the highest appropriate dose is recommended. Home-based therapy can facilitate early intervention. If additional rFVIIa therapy is required after the initial dose, rFVIIa 90μgkg -1 may be administered at 2-3h intervals. Treatment should be tailored to bleed site/severity, recognizing the advantages of appropriate adjunct therapy. Questionnaire results suggested that many respondents adopted strategies in line with the recommendations. Most (36/46) recommended initial therapy within 1h of bleed onset. rFVIIa 270μgkg -1 was the most frequently prescribed/recommended initial dose for paediatric (aged ≤15years; 22/44 respondents) and adult (aged >15years; 23/44 respondents) patients. However, there may be opportunity for improved bleed management on occasion, with regard, for instance, to dosing and dose interval. To secure and maintain predictable efficacy with rFVIIa, judicious dose selection and treatment timing are important, together with adjunct therapy where necessary. As inhibitor patients present with different bleeding scenarios, a tailored treatment approach should be adopted. © 2011 Blackwell Publishing Ltd.
Dargaud Y.,Unite dHemostase Clinique
Oncologie | Year: 2012
The pathogenesis of the prothrombotic state of cancer patients ismostly due to the ability of cancer cells to activate the coagulation system. There are several complex and not fully understood interactions between the malignant cell and the clotting system. Tumour cells possess the capacity to interact with the haemostatic system in multiple ways. The principal mechanisms include the expression of haemostatic proteins by tumour cells, the production of inflammatory cytokines and the direct adhesion of tumour cells to platelets, endothelial cells and monocytes. This paper summarizes the prothrombotic mechanisms of tumour cells and their role in both coagulation and tumour growth and metastasis. © 2012 Springer-Verlag France.
Nair S.C.,Christian Medical College |
Dargaud Y.,Unite dHemostase Clinique |
Dargaud Y.,University of Lyon |
Chitlur M.,Wayne State University |
Srivastava A.,Christian Medical College
Haemophilia | Year: 2010
There is a potential for significant paradigm shift in the assessment of haemostasis from the conventional plasma recalcification times, such as prothrombin time (PT) and activated partial thromboplastin time (APTT), which correspond to artificially created compartments of haemostasis to tests that assess the entire process in a more physiological and holistic manner. These include the thrombin generation test, thromboelastogram and the clot wave form analysis. While these tests have been described many years ago, there is renewed interest in their use with modified technology for assessing normal haemostasis and its disorders. Although early data suggest that they can provide much greater information regarding the overall haemostasis process and its disorders, many challenges remain. Some of them are possible only on instruments that are proprietary technology, expensive and are not widely available. Furthermore, these tests need to be standardized with regard to their reagents, methodology and interpretation, and finally, much more data need to be collected regarding clinical correlations with the parameters measured. © 2010 The Authors. Journal compilation © 2010 Blackwell Publishing Ltd.